drugset
drugset / Trial / NCT05374226

A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

NCT05374226 ↗

Phase 1 Unknown 172 enrolled Suzhou Kebo Ruijun Biotechnology Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors/lymphomas. The study includes JS019 monotherapy dose escalation, dose expansion and indication expansion stages to investigate the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of JS019 as monotherapy.

Timeline

Start
2022-03-31
Primary completion
2023-12-11
Completion
2024-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject JS019 Monoclonal antibody 0.3 mg/kg Intravenous
Subject JS019 Monoclonal antibody 1 mg/kg Intravenous
Subject JS019 Monoclonal antibody 3 mg/kg Intravenous
Subject JS019 Monoclonal antibody 10 mg/kg Intravenous

Indications

neoplasm